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S U M M A R Y
Background: In Turkey, the Haemophilus inﬂuenzae type b–tetanus toxoid conjugate vaccine (Hib) was
replaced by the combined diphtheria–tetanus–acellular pertussis and inactivated polio vaccine (DTaP–
IPV/Hib) in 2008. This shift to the new schedule created different cohorts of vaccinated children as a
consequence of the different schedules used. We evaluated the immunogenicity of the Hib vaccine in
infants vaccinated with these different schedules.
Methods: Three groups of children were evaluated: group 1 comprised 145 infants vaccinated with
diphtheria, tetanus, and whole cell pertussis (DTwP), oral polio vaccine (OPV), and Hib vaccines
simultaneously at separate sites; group 2 comprised 204 infants vaccinated with the DTaP–IPV/Hib
combined vaccine; group 3 comprised 100 infants vaccinated with a mixed schedule of DTwP, OPV, and
Hib for the ﬁrst one or two doses, followed by DTaP–IPV/Hib vaccine to complete the series.
Results: Anti-polyribosylribitol phosphate (anti-PRP) titers 0.15 mg/ml were similar in groups 1, 2, and
3. However, in group 1, who received all the vaccines at separate sites,  l.0 mg/ml long-lasting antibody
titers and anti-PRP geometric mean titers were higher (p = 0.001).
Conclusion: This study showed that even one dose administered in combination with other vaccines in a
primary series decreased the level of anti-PRP.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
In 2007, the Haemophilus inﬂuenzae type b–tetanus toxoid
vaccine (Hib; Act-Hib1) was added to the national vaccination
schedule for infants in Turkey. Over a 1-year period, in addition to
live oral poliovirus vaccine (OPV), infants were administered
diphtheria, tetanus, and whole-cell pertussis (DTwP) and Hib
vaccines as two simultaneous injections at separate sites as part
of their primary vaccination course. In 2008 the combined
diphtheria–tetanus–acellular pertussis, inactivated polio vaccine
and conjugated Hib capsular polysaccharide (DTaP–IPV/Hib;§ This manuscript was presented at the Annual Meeting of the European Society for
Social Pediatrics and Child Health (ESSOP 2010), Kus¸ adası, Turkey, October 13–16,
2010, as a poster entitled ‘‘Immunogenicity of a Haemophilus inﬂuenzae type B tetanus
conjugate vaccine when administered separately or in combined vaccines for primary
immunization in two consecutive national schedules in Turkey’’.
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1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2012.01.005Pentaxim1) vaccine became part of the national childhood
immunization program.
In many countries, the incidence of invasive Hib disease among
children aged <5 years declined markedly after the inclusion of Hib
conjugate vaccines into the infant vaccination schedules.1 Howev-
er a reduction in anti-polyribosylribitol phosphate (anti-PRP) titers
was observed when Hib conjugate vaccine was administered in a
single injection with diphtheria–tetanus–acellular pertussis
(DTaP)2–5 or DTwP6 when compared with the responses of infants
who received these vaccines simultaneously but at separate sites.
Another study showed that concurrent IPV seemed to interfere
with the anti-PRP response to the DTaP/Hib vaccine.7 In other
studies, antibody titers to PRP in infants who had received the Hib
and DTwP8 or DTaP9,10 vaccines separately or in combined vaccines
were similar. The clinical signiﬁcance of antibody levels is not yet
known.
The change in routine Hib vaccination scheme from separate
vaccine administration to the combined form created different
cohorts of children in Turkey: (1) those who were vaccinated with
the separate Hib vaccine in 2007; (2) those who had their initialses. Published by Elsevier Ltd. All rights reserved.
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with the combined vaccine, and (3) those born in 2008 who were
vaccinated with the combined form for all primary doses. The
immunogenicity of these schedules might differ from each other.
Differences between the cohorts in relation to the risks of invasive
Hib disease may be revealed by invasive Hib disease surveillance.
To interpret the outcome of any surveillance, the initial immune
responses of the combined or simultaneous vaccination schemes
should be known. Therefore in this study we evaluated the
immunogenicity of the Hib vaccine among these three cohorts of
children vaccinated with the different schedules.
2. Materials and methods
2.1. Study population
The study was conducted between May 1, 2008 and April 30,
2009. All healthy infants aged 12 months who attended the Gazi
University Faculty of Medicine Well Child Clinic within this period
were enrolled in the study after obtaining written informed
consent from the parents. All infant primary vaccinations had been
completed at the same clinic 6 months before they were enrolled in
the study. Those who had a chronic disease or who had been
administered an immunosuppressive therapy were excluded.
One hundred and forty-ﬁve infants were vaccinated with DTwP,
OPV, and Hib (Act-Hib) vaccines simultaneously at separate sites
and formed group 1; 204 infants were vaccinated with the DTaP–
IPV/Hib combined vaccine (Pentaxim) at 2, 4, and 6 months of age
and formed group 2; 100 infants were vaccinated with a mixed
schedule (ﬁrst one or two doses administered as DTwP + OPV + Hib
and the primary series completed with DTaP–IPV//Hib) and formed
group 3. Hence, a total of 449 infants were included.
The study protocol was approved by the Ethics Committee of
Gazi University Medical Faculty before the study was started, and
procedures complied with the latest version of the Declaration of
Helsinki.
2.2. Vaccines
In 2007, infants were vaccinated with DTwP vaccine (Triple
Antigen; Serum Institute of India), the commercial Hib vaccine
(Act-Hib; Pasteur Me´rieux Serums et Vaccins, France), and OPV
(Sabin Trivalent; Bio Farma, Indonesia). In 2008, the DTaP–IPV/Hib
vaccine (Pentaxim; Pasteur Me´rieux Serums et Vaccins) was
applied. Parenteral vaccines were injected intramuscularly into the
thigh, and OPV was administered by the oral route.
The DTwP vaccine contains diphtheria toxoid 25 Lf, tetanus
toxoid 5 Lf, and pertussis toxoid 4 IU adsorbed on aluminum
phosphate 1.5 mg, with thiomersal 0.01% as preservative. OPV
contains poliovirus not less than 106.0 CCID50 (50% cell culture
infective dose) for type 1, 105.0 CCID50 for type 2, and 105.8 CCID50
for type 3. Hib vaccine contains 10 mg of polyribosylribitolTable 1
Anti-PRP levels 6 months after primary vaccination
Anti-PRP IgG (mg/ml) DTwP + OPV + Hiba (n = 145), n (%) DTaP–
0.15d 139 (95.9) 186 (
1.0e 101 (69.7) 91 (
GMT (mg/ml) 1.87 0.9
Anti-PRP, anti-polyribosylribitol phosphate; GMT, geometric mean antibody titer.
a DTwP + OPV + Hib: diphtheria, tetanus and whole-cell pertussis and oral poliomyel
b DTaP–IPV/Hib: diphtheria–tetanus–acellular pertussis and inactivated polio vaccin
c Mixed group: DTwP + OPV + Hib or DTaP–IPV/Hib.
d Seroprotective level.
e Long-term protection level.
f Logarithmic transformation was applied to the antibody titer values for the statistiphosphate covalently linked to 20 mg of tetanus toxoid (PRP–T)
and was supplied in the lyophilized form in single-dose vials.
Reconstitution was carried out at the time of injection with 0.5 ml
of diluent (saline 0.4% w/v).
DTaP–IPV/Hib contains diphtheria toxoid 30 IU, tetanus
toxoid 40 IU, adsorbed pertussis toxoid 25 mg, ﬁlamentous
hemagglutinin 25 mg, inactivated poliovirus type 1 (40 DAgU),
inactivated poliovirus type 2 (8 DAgU), and inactivated poliovirus
type 3 (32 DAgU), and PRP–T 10 mg vaccine in lyophilized form,
reconstituted at the time of injection.
2.3. Serology
Blood samples were drawn 6 months after the third dose, when
all infants were 12 months of age. Serum was promptly prepared
and stored at 20 8C until blinded serological analyses were
performed. Concentrations of PRP antibodies were assayed using
the micro enzyme immunoassay (EIA) method (VaccZYME Hib IgG
enzyme immunoassay kit; The Binding Site Ltd, UK) and expressed
in mg/ml. The assay cut-off was set at 0.15 mg/ml. Geometric mean
antibody titers (GMT) were calculated for each group, with
concentrations below the cut-off being attributed a value of
one-half of the cut-off value.
2.4. Statistical analysis
The one-way analysis of variance (ANOVA) test was used for
comparisons of the antibody levels between the three groups after
logarithmic transformation. A p-value of <0.05 was considered to
be statistically signiﬁcant. Tukey’s HSD test was used as a post-hoc
test for multiple comparisons when the one-way ANOVA test
revealed statistically signiﬁcant differences between the three
groups.
3. Results
The anti-PRP antibody responses of the 449 infants are shown
for each group in Table 1. Six months after the third dose of vaccine,
over 90% of children in each group attained seroprotective levels of
PRP antibody (0.15 mg/ml). The highest positivity rate was seen
in group 1 (95.9%); in the mixed group it was lower compared to
group 1 (93%), and the rate was lowest in the combined vaccine
group (91.2%). These differences were not statistically signiﬁcant
(p = 0.235).
Two hundred and thirty-nine (53.2%) of the infants had
antibody levels considered to confer long-term protection
(1.0 mg/ml). Group 1, who received all the vaccines separately,
appeared to have long-lasting antibody levels higher than the
other groups (p = 0.001).
The anti-PRP GMT values differed signiﬁcantly between group 1
and the other groups. Group 1, who received all the vaccines
separately, appeared to have antibody levels higher than group 2IPV/Hibb (n = 204), n (%) Mixedc (n = 100), n (%) p-Value
91.2) 93 (93) 0.235
44.6) 47 (47) = 0.001
0 0.93 = 0.0001f
itis and Haemophilus inﬂuenzae type b–tetanus toxoid vaccine.
e/Haemophilus inﬂuenzae type b–tetanus toxoid vaccine.
cal analysis.
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signiﬁcant difference between the antibody levels in group 2 and
group 3 (p = 0.913).
4. Discussion
Our study aimed to evaluate the immune response elicited by a
conjugated Hib vaccine at 6 months after completion of the
primary vaccination series, in infants who were vaccinated with
different schedules over consecutive years, either associated or
combined with other pediatric vaccines used routinely in our
country (namely DTwP, DTaP, and IPV or OPV). As in many previous
studies,2–5 we also observed some differences with regard to the
GMT values of PRP antibodies, with a tendency for a stronger
response in the group who received DTP, OPV, and Hib vaccines
separately.
An anti-PRP concentration 0.15 mg/ml has been suggested to
be seroprotective.11 Despite the observed differences in antibody
levels 6 months after primary immunization, over 90% seroprotec-
tion rates were obtained for all groups.
Concentrations 1.0 mg/ml are reported to correlate with long-
term protection.11 In the present study, and in many others,3–5,2 it
was found that high antibody concentrations (1.0 mg/ml) were
obtained in the group who received all vaccines separately. This
ﬁnding may indicate that the protection of Hib vaccine will be
short when the vaccine is applied combined with other vaccines.
This study revealed that both GMT values and antibody levels
1.0 mg/ml were decreased in the combined schedule, even if not
all of the primary doses were administered in the combined form.
Although the risky age for Hib infections in children is relatively
short and long-term immunity may not be necessary, there is still
insufﬁcient information regarding the requirement for long-lasting
antibody levels. Long-lasting antibody levels may be of particular
importance for children who go on to develop secondary immune
deﬁciencies.
The reduced anti-PRP antibody titers observed when the Hib
conjugate vaccine was administered in a single injection with DTaP
and IPV were reported not to be associated with an increased
number of invasive Hib cases.12 Greenberg et al. recently reported
that incidence rates of invasive Hib disease among Canadian
children aged <5 years declined markedly after the introduction of
Hib conjugate vaccines, and the disease has remained under
control with exclusive use of DTaP–IPV/Hib vaccine.1 On the other
hand McVernon et al.13 retrospectively compared vaccine for-
mulations given to fully vaccinated Hib cases with those
administered to fully immunized age-matched controls using
conditional logistic regression. More cases than controls had
received all three doses of the infant primary course as DTaP–Hib,
compared with two or three doses of Hib vaccine (conditional odds
ratio 6.77, 95% conﬁdence interval 3.26–14.07).
The factors responsible for the reappearance of invasive Hib
disease cases in vaccinated children are not clear. Breukels et al.
studied the anti-Hib antibody production both quantitatively
and qualitatively in 12 patients who experienced Hib failure.
Both anti-Hib antibody concentration and immunoglobulin-G2
anti-Hib antibody avidity were signiﬁcantly lower in patients
who experienced Hib failure, at the onset of disease and after
convalescence, when compared with controls. This ﬁnding
suggests that the patients who developed invasive Hib disease,
despite having received three or four Hib conjugate vaccinations,
were inadequately primed by these vaccinations.14 Lee et al.
performed a retrospective study on 251 Hib vaccine failures and
reported that children who experienced Hib disease despite
vaccination appeared to have a defect in immunological priming,
leading to a qualitative difference in Hib-speciﬁc memory B
cells. Low anti-PRP antibody avidity decreases the functionalactivity of anti-PRP antibody in the serum of these children
experiencing vaccine failure, leading to disease.15 Eskola et al.
also suggested that the lower antibody responses were not
associated with impaired function of the antibodies induced,
nor, and possibly more importantly, with the induction of
immune memory against Hib.16 Some studies have demonstrat-
ed the development of anti-PRP immune memory at an early
age, after completion of a three-dose primary vaccination course
of combined DTaP–IPV/Hib vaccine.10,17 Many investigators
believe that immune memory is most important, and even if
the combined vaccines for primary immunization caused a
decrease in anti-Hib antibody response after primary immuni-
zation, higher antibody responses to booster doses in children
vaccinated with combined vaccine can be considered to be
protective for invasive Hib disease. Nevertheless the duration of
protection is not known accurately and continued surveillance of
invasive Hib infections among children who have been
vaccinated with different schedules can guide new vaccination
strategies. Indeed, an 18-month-old infant vaccinated with
combined vaccine was reported to have invasive Hib infection
although he had no immune deﬁciency.18
It is well documented that Hib vaccine provides higher levels of
PRP antibodies when administered as a separate antigen. Previous
studies have compared separate vaccination with combined
vaccination for all primary series. Our study also included a group
consisting of children who received both separate and combined
vaccination for the primary series. The results indicate that even
one dose of combined vaccine lowers the level of antibody against
PRP–T.
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